Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer.

JCO Clin Cancer Inform · 2024 · PMC11658027 · PMID 39671539

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In Data Set C, the model identified OS benefit with an HR of 0.36 (95% CI, 0.14 to 0.92; P = .026) but did not reach statistical significance for PFS.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.